Health Care Cutting biosimilar red tape could save billions Europe designates all biosimilars as interchangeable with original biologics. It's time for the United States to do the same.
Prescription Drugs Aduhelm decision exposes Medicaid to billion-dollar costs To make Medicare and Medicaid more sustainable, both programs should have the liberty to exclude coverage of low-value drugs.
Prescription Drugs New FDA chief pressured to slow the pace of new drug approvals In order to accelerate FDA approval of more drugs, the agency should be more willing to pull drugs that fail in the real world.
